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Abstract
Protective immune defences are dependent upon critical roles played by dendritic cells 
(DCs), rendering them important targets for both vaccine delivery and virus infec-
tion. Studies in these areas led to successful development of targeted vaccine delivery, 
including synthetic virus-like particle (SVLP) and nanoparticulate RNA vaccines. A 
major consideration is DC endocytosis, whereby the different endocytic routes influ-
encing the outcome. Rapid clathrin-mediated endocytosis likely favours degradative 
pathways. Slower processes such as macropinocytosis, caveolar endocytosis and retro-
grade transport to endoplasmic reticulum relate more to the processing rates leading 
to antigen presentation by DCs. These pathways are also influential in promoting the 
initiation of virus replication following infection. DC endocytosis of RNA viruses and 
RNA vaccines must lead to cytosolic translocation of the RNA for translation, relating 
to the process of antigen cross-presentation. One can learn from observations on both 
virus infections and cross-presentation for delivering RNA vaccines. Accordingly, 
recent advances in nanoparticulate delivery have been applied with self-amplifying 
replicon RNA (RepRNA), providing efficient delivery to DCs and promoting replicon-
encoded antigen translation. Through realising the important relationships between 
DC endocytic pathways and induction of immune responses, delivery of SVLP and 
RepRNA vaccines to DCs offers high value for the development of future synthetic 
vaccine platforms.
Keywords: dendritic cells, endocytosis, virus infection, vaccines, SVLPs, self-amplifying 
RNA
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1. Introduction
While protective immune defences are reliant upon robust antibody-mediated (B-lymphocyte) 
and concomitant T-lymphocyte response, their development is dependent on antigen deliv-
ery leading to processing and presentation by dendritic cells (DCs), a critical player for 
robust immune defence development, and therefore efficacious vaccination [1–9]. Induction 
of  antibody (humoral) and cell-mediated immune (CMI) defences requires virus or vaccine 
interaction with the conventional DC (cDC) subsets, the ‘professional antigen presenting 
cells’ [3, 6–12] (Figure 1). The manner by which these cDCs handle the antigen derived from 
an infection or vaccination defines the characteristics of adaptive immune defence develop-
ment (Figure 2). Considering that many pathogen infections induce both humoral and CMI 
defences, vaccines inducing both arms of immune defence increase the potential for inducing 
robust immune defences. Accordingly, live attenuated vaccines should more closely mimic 
pathogen infection and therefore induce immune defence characteristics more related to 
 convalescent immunity.
Understanding the cell biological elements providing DCs with their functionality has 
been  possible from studies on both effective convalescent immunity and that induced by 
efficacious vaccination. Whether the studies focussed on virus infection or efficacious vac-
cine delivery, particular routes of endocytosis were observed to dominate. Through this, the 
power of DCs as the ‘professional antigen-presenting cell’ was determined [1, 3, 4, 6–8]. Yet, 
most current vaccines are inactivated or subunit/split vaccines. Being non-replicative, only a 
limited amount of antigen can be provided, namely that within the vaccine dose, in contrast 
to the much greater antigen levels produced during infection and from a live vaccine. Such 
non-replicative vaccines induce more restricted immune defence characteristics, in terms 
of humoral versus CMI immunity and the robustness (longevity) of that immunity, than 
observed with convalescent immunity or that induced by a replicating vaccine.
Of course, pathogen infection can induce undesirable clinical symptoms influencing the 
 development of convalescent immune defence, which can be avoided by employing non-
pathogenic replicating vaccines. Unfortunately, safe and efficacious live vaccines are not 
available for the majority of pathogens. Nonetheless, lessons can be learnt from convalescent 
immunity [9, 13]. A major consideration is the capacity of replicating vaccines to mimic the 
pathogen infection such as producing several rounds of antigen production, increasing the 
effective antigen dose, involving different antigen-presentation pathways, promoting different 
arms of immune responses and thus increasing the efficacy of immune defence induction [9].
Resolution of this situation is showing promise from the more recent application of synthetic 
biology to create both synthetic virus-like particles (SVLPs) [14–16] and self-amplifying/rep-
licating RNA (replicon or RepRNA) vaccines [9, 13, 17–20], but also from advances in studies 
on virus infections. It has been observed that the majority of endocytosed material may well 
traverse rapid clathrin-mediated pathways, which is more likely favouring degradation of 
the internalised material [9, 21–25] (Figure 3, pathway (a)). Slower kinetics of endocytosis 
would favour the processing required for a particular vaccine to prove efficacious or a virus to 
 initiate its replication. Such outcomes are seen with macropinocytosis and caveolar endocytosis 
(Figure 1; Figure 3 pathway (b)), as well as endocytosis into sorting endosomes for retrograde 
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Figure 1. Generalised overview of the two main cDC subsets—cDC1 and cDC2—following endocytosis of virus or 
vaccine; processing pathways of endocytosed material leading into MHC Class I and MHC Class II presentation of 
the antigenic peptides to T-lymphocytes; delivery of antigen to B-lymphocytes; resultant initiation of antigen-specific 
immune defences and antibody production.
Dendritic Cell Endocytosis Essential for Viruses and Vaccines
http://dx.doi.org/10.5772/67779
101
transport though the Golgi complex into the endoplasmic reticulum (ER) (Figure 1; Figure 3 
pathway (c)) [9, 26–29].
Further insight into the versatility of DC endocytic process has come from studies on initiation of 
RNA virus replication [25]. These have identified certain points of convergence with cross-pre-
sentation of protein-based vaccines, and thus initiation of RNA vaccine translation of encoded 
antigens [9]. Importantly, both cross-presentation of antigen and initiation of  endocytosed 
Figure 2. DC subset interaction with different T-lymphocyte subsets. Following processing and presentation of the 
derived antigen peptides to antigen-specific T
h
- or T
reg
-lymphocytes, the patterns of cytokine communications are shown. 
These are important for defining the characteristics of the developing immune response. The endocytic processes involved 
are likely to be clathrin-independent endocytosis such as macropinocytosis, caveolar endocytosis or phagocytosis.
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RNA translation require DC endocytosis leading into cytosolic  translocation. Endocytosis for 
cross-presentation delivers exogenous antigen via cytosolic translocation into pathways of 
polyubiquitination; this directs processing by the immunoproteosome  (cross-presentation) for 
presentation via major histocompatibility complex (MHC) Class I (Figure 1, Figure 3 pathways 
Figure 3. A schematic representation of the main endocytic processes functional within DCs in terms of processing 
internalised material for (a) degradation, (b) MHC Class II presentation, (c) MHC Class I presentation and (d) cytosolic 
release for cross-presentation via the immunoproteasome or translation of RepRNA vaccines. The lower portion of the 
image highlights certain aspects of endosomal release from endocytic vesicles during the early stages after acidification 
by interaction with early endosomes.
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(c) and (d)) [9, 30–32]. Similarly, endocytosed vaccine RNA would be delivered by cytosolic 
translocation into the ribosomal translation sites within the cell for translation of the encoded 
vaccine antigens [9, 25].
Cationic entities, particularly in a vaccine formulation, have been characterized for their 
capacity to promote endocytic vesicle perturbation towards cytosolic translocation [9, 13]. Yet, 
there are other considerations. Initiation of a virus infectious process may involve the viral 
membrane (with enveloped viruses) or virus surface proteins; thus, cytosolic translocation 
can be facilitated by membrane fusion and ‘flipping’, or through formation of ion  channels 
and elaborating membrane pores for delivery of the RNA genome [25]. Application of this 
knowledge has recently been employed with synthetic biodegradable nanoparticulate vehi-
cles for enhancing delivery of self-amplifying/replicating RepRNA vaccines to DCs [9, 13, 
17–20, 33–35] (Figure 3 pathway (d)). Whilst success with this approach has been forthcoming 
with mRNA vaccine delivery to DCs [9, 36, 37], delivery of the larger replicon RepRNA mol-
ecules has required additional considerations. This may be due to the likely increased com-
paction of these larger RNA molecules by the delivery vehicle, but other events important 
to the virus genome from which RepRNA is derived must be considered, including the role 
of cellular micro-RNAs (miRNA) and divalent cations. Nonetheless, nanoparticulate delivery 
technology has been adapted to deliver RepRNA to DCs (see below), leading to promotion 
of the replicon-encoded antigen translation in vitro and in vivo [13, 17–20, 33, 34]. The work 
identified important relationships between the DC endocytic pathways and ultimate induc-
tion of immune responses by the nanoparticle-delivered RepRNA, relating to characteristics 
observed following virus infection.
2. Dendritic cells: sentinels of immune defence
Dendritic cell (DC) subsets are found in many sites of the body, which determines their 
roles in developing and regulating immune defences (Figure 4) [1–12]. Together with MΦ, 
tissue and mucosal DCs are in the front line for encounter with and response to a virus or 
vaccine. These ‘local’ DCs and MΦ initiate the inflammatory response recruiting additional 
DCs together with monocytes, differentiating into DCs and MΦ, to augment local cell activ-
ity (Figure 4). Both the receptor repertoire and the endocytic processes employed by DCs 
and MΦ are closely related. Nonetheless, major distinctions exist, notably the recruitment of 
 lysosomal proteases to the acidifying endocytic pathways is observed earlier and at higher 
levels in MΦ compared with DCs [38].
Dendritic cells are the central players for effective convalescent immunity, efficacious 
 vaccination and maintenance of tolerance (Figure 2; Figure 4) [1, 3, 4, 6–8]. They are capable 
of both MHC Class II presentation (Figure 1; Figure 2), MHC Class I presentation, cross-
presentation (Figure 1) [30, 32, 39–43] and antigen delivery to B lymphocytes (Figure 1) [44, 45], 
as well as regulating immune responsiveness and immune tolerance (Figure 2; Figure 4) [6, 
46–53]. Therein lie two important aspects of DC biology—their high capacity for endocytosis 
together with the diverse network of routes employed (Figure 3) and different subsets tend 
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to dominate particular processes [3–5, 9, 12, 21–23, 54–56]. Although particular endocytic 
routes may dominate under certain interactions between DCs and virus or vaccine, more than 
one endocytic route will often be involved [9, 22, 56]. Indeed, using SVLP vaccines [14, 15], 
multiple endocytic routes have been identified. While macropinocytosis played a major role, 
additional endocytic routes were operative, as observed with mature DCs no longer employing 
macropinocytic activity [14].
Figure 4. Dendritic cell subsets can be defined with respect to their sites of ‘residence’ in the body, wherein they act as 
sentinels for sampling the environment, to maintain tolerance and respond to ‘foreign’ material posing a ‘danger’ to the 
host. This is particularly notable at mucosal surfaces for controlling local tolerance through anti-inflammatory processes, 
while ensuring responsiveness against pathogenic entities and mucosal vaccines.
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3. Application of multiple endocytic pathways
Combining studies on both virus infection of and vaccine delivery to DCs have led to the creation 
of new vaccine formulations, such as SVLP vaccines [14, 15] and the self- amplifying RepRNA 
vaccines [9, 17–19, 33]. While clathrin-mediated endocytosis has often been  implicated with 
both virus infection and vaccine delivery [9, 22, 25, 55–57], the rapidity of the process and 
levels of enzymatic activity therein would favour a more degradative pathway, rather than one 
promoting antigen processing or RNA-release for translation. Certainly, rapid clathrin-medi-
ated endocytosis would create a detrimental environment to the survival of both RNA viruses 
and RNA vaccines (Figure 3, pathway (a)).
Accordingly, antigen must be processed to reach either the MHC Class I or MHC Class II 
assembly sites for appropriate antigen presentation (Figure 3, pathways (b), to (d)); RNA 
must be processed to reach the ribosomal translation machinery. Both exogenous antigen 
and RNA must avoid the degradative capacities of the late endosomes and, in particular, the 
lysosomes. Antigen being processed through the maturing endosomal system has to target 
the MHC Class II compartment (MIIC), for MHC Class II presentation, providing processing 
rather than degradation by lysosomes. With MHC Class I presentation, endocytosed exog-
enous antigen has to transfer from the endocytic pathway to the cytosol—cytosolic translo-
cation. This facilitates the cross-presentation processing pathway via immunoproteasomes. 
An important characteristic is that the cytosolic translocation must be effected at a relatively 
early stage of endosome-mediated acidification of endocytic vesicles (see below). As for 
RNA, from viruses or vaccines, the cytosolic transfer for translation has to occur before the 
maturing endosomal system becomes too degradative; that is viral RNA genomes and 
RNA vaccines must escape the maturing endosomal system while still capable of translating 
[9, 38, 40, 43, 58].
While these differential processing pathways of DCs are important for ensuring efficient 
 provision of antigen in the correct form for immune defence development, an additional pro-
cess is essential, namely, endocytosis leading into ‘danger’ signalling. From within the endo-
somal system, this involves toll-like receptor (TLR)-containing endosome-like  structures, 
which in turn are unlikely to provide antigen presentation and certainly detrimental to RNA 
release for translation. Following cytosolic translocation of RNA, danger signalling can be 
effected through cytosolic detectors such as the retinoic acid-inducible gene-I (RIG-I) fam-
ily of helicases (see below). Accordingly, DCs employ different endocytic mechanisms and 
pathways to ensure correct processing of antigen, appropriate cytosolic translocation for cross-
presentation, cytosolic translocation of RNA for translation, and appropriate delivery of anti-
gen-based or RNA-based entities to the ‘danger’ signalling pathways.
4. Dendritic cell sensing
With DCs being an important sentinel of the immune system, the receptors on these cells play 
critical roles in different aspects of host environment surveillance (Figure 5). On the one side, 
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particular DC receptors are more involved in pathogen or vaccine uptake. In addition to this, 
DC handling of material ‘foreign’ to the host can lead to ‘danger’ recognition, which effec-
tively determines immune activation as opposed to tolerance induction. Dendritic cell pattern 
recognition receptors (PRRs) recognise pathogen-associated or danger-associated molecular 
patterns (PAMPs and DAMPs), playing major roles in this recognition and ultimate signalling 
of the DCs.
Dendritic cell receptor ligation determines the manner by which DCs endocytose and the out-
come of the DC activity. One important consequence of ligating certain receptors is the 
 induction of inflammatory reactions (see Figure 2 and Figure 4), the characteristics of which 
relate to the receptors involved [5, 59, 60]. While PRRs such as toll-like receptors (TLRs), 
complement receptors and mannose-binding receptors (Figure 5) are important for inflam-
matory responses, both these and other receptors including other C-type lectins, integrins and 
CD44 can enhance ‘foreign’ material binding to and internalisation by the cells into endocytic 
processing pathways [5, 9, 61–63]. For example, ligation of TLRs, siglecs, galectins and CD14 
can promote antigen uptake as well as activating innate defence processes, either alone or 
in co-operation with C-type lectins or integrins [9, 64, 65]. Moreover, different DC receptors 
can promote uptake into different endocytic pathways. For example, cholera toxin may be 
targeted to caveolar endocytic pathways and the ER, whereas autocrine mobility factor associ-
ates more with the ER [66]. While simian virus 40 (SV40) also targets to the ER, both this and 
cholera toxin are observed in recycling endosomes prior to retrograde transport into the Golgi 
and ER [26–29].
In addition to DC sensing their environment via cell surface PRRs such as TLR2 heterodimers 
and TLR4, endocytosed material can also be sensed. Vesicular TLR2 can detect lipopeptides 
Figure 5. Examples of known DC receptors, demonstrating their wide range of capacities for sampling the host environment. 
These receptors also offer the potential for targeting vaccines to DC, particularly with the new synthetic vaccines employing 
nanoparticulate delivery vehicles.
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buried deep within bacterial cell walls following endosomal degradation of the latter to 
expose the lipopeptides. This was proven using SVLPs carrying TLR2 ligands within their 
hydrophobic cores [15]. By employing such SVLPs, there was no influence of interaction with 
cell surface TLR2 heterodimers, as is the case with bacteria and yeast particles through the 
lipoteichoic acid and peptidoglycan moieties in their cell walls.
Additional intracellular PRRs are also involved in detecting ‘foreign’ RNA—vesicular TLR3 
and TLR7, and cytosolic sensors including helicases [67–69]. RNA sensing is an important 
issue for RNA virus infection and RNA vaccine delivery. Pathogen-associated molecular 
patterns (PAMPs) associated with ‘foreign’ RNA are generally formed through RNA modi-
fications or secondary structures not normally found within the cells. TLR3 and TLR7 can 
respond to dsRNA and ssRNA structures on the ‘foreign’ RNA, respectively, such PRR activity 
being linked with processing via the endosomal system. Yet the RNA associated with RNA 
virus infections as well as with delivery of RNA vaccine can be translocated to the cytosol 
through action of the virus or vaccine particles (see below). Under these conditions, cytosolic 
sensors become important for detecting RNA-associated PAMPs.
5. Cytosolic PRR activity
Cytosolic helicases can detect RNA translocated to the cytosol from vesicular structures. 
The cytosolic helicases of the RIG-I-like receptors (RLRs) family recognise RNA-associated 
PAMPs through their helicase domain and C-terminal repressor domain (RD); the conse-
quential triggering of intracellular signalling cascades is effected via the caspase-recruitment 
(CARD) domains [70]. As with the RNA-sensing TLRs, RLRs can recognise PAMPs associated 
with either ssRNA or dsRNA. The latter come from the dsRNA intermediates derived from 
replicating viral genomic RNA or RepRNA; single-stranded RNA molecules can also form 
double-stranded sequences during the hairpin-folding for their secondary structures, the 
length of which will determine their detection as PAMPs [71]. In addition to such structures, 
RNA bearing a 5’-triphosphate will also be sensed by helicases.
Within the RLR family, RIG-I responds to both short dsRNA sequences and ssRNA bearing 
a 5’-triphosphate; MDA-5 responds more to long dsRNA [70]. 5’-triphosphate structures 
are often required by positive-strand RNA viruses (termed ‘positive strand’ due to the capac-
ity of the viral genome to function as an mRNA) to ensure ribosomal entry for translation. 
During the replication of RNA viruses and RepRNA, dsRNA ‘replicative intermediates’ are 
formed to generate progeny ssRNA (hence the ‘self-amplifying term associated with RepRNA 
vaccines). Thus, DCs endocytosing RNA viruses or vaccines capable of self-amplification 
would respond to dsRNA replicative intermediates, in addition to the double stranded 
secondary structures in the endocytosed RNA, and 5’-triphosphate if present.
This ‘danger’ sensing of RNA structures provides a good example of the divergence displayed 
by different DC subsets, and the influence on the cytokine profiles induced. Plasmacytoid DCs 
(pDCs) tend more to use TLR3 and TLR7 sensing; other cells will employ the cytosolic sensors 
of RLRs and oligomerization domain (NOD)-like receptors (NLRs), which also respond to 
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dsRNA structures [70]. While RLR- and TLR-mediated activation leads to type I interferon 
and pro-inflammatory cytokine production, dependent on the DC type, NLR-mediated 
activation favours IL-1β induction; it is also important to note that dsRNA sensing by NLRs 
is involved in the regulation of the induced responses [70].
Thus, ‘danger’ recognition can lead to particular cytokine profiles dependent on the sensing 
receptor and DC subset involved. The pDC sensing of RNA by TLR3 and TLR7 (and DNA 
by TLR8/9) leads to the production of notably high levels of IFN-α and TNF, particularly in 
response to infection. In addition to their anti-viral properties, these cytokines provide the 
necessary signals to promote appropriate cDC maturation, essential for ensuring that anti-
gen presentation to lymphocytes promotes the development of an antigen-specific adaptive 
immune response. However, induction of cytokine production by DCs, cDCs and pDCs, will 
not always prove beneficial in promoting effective immune defence. For example, viruses 
such as influenza virus and haemorrhagic disease viruses can induce excessive levels of IFN-α 
and other inflammatory cytokines, leading to the so-called cytokine storm and subsequent 
immunopathological problems [72–75]. Even viruses not renowned for inducing such events 
can be prove troublesome. For example, foot-and mouth disease virus infection in pigs can 
increase IL-10 production by DCs, with a consequential negative influence on antigen pre-
sentation and T-lymphocyte activation; in contrast, immune complexes with foot and mouth 
disease virus are potent inducers of IFN-α by pDCs [76, 77].
Such studies on virus infection of DCs have helped to define conditions beneficial for 
the host, and therefore what is required for efficacious vaccination. Dendritic cell cytokine 
induction is certainly critical for inducing maturation of cDCs, an essential requirement for 
both migration into lymph nodes and efficient presentation of antigen leading to activation 
of T-lymphocyte responses [2, 7, 10, 62]. Overall, one should consider that targeting slower 
endocytic processing pathways rather than targeting the more rapid and degradative path-
ways would prove crucial.
6. Comparative endocytic processes within DCs
The aforementioned differences between MΦ and DCs give an important insight into the 
characteristics of endocytic processing. Dendritic cells degrade endocytosed material at 
slower rates, with an overall less acidic phagosomal/endosomal pH than MΦ [38]. These 
 characteristics relate to the different biological roles of the two cell types. On the one 
hand, DCs are more important for processing and delivering antigen to activate lymphocyte 
responses. Conversely, MΦ play a more significant role in innate immune cell defence, notably 
pertinent in the removal and destruction of infectious pathogens, as well as entities present-
ing a danger to the host, such as damaged or dying cells. Nonetheless, these roles are neither 
absolute nor mutually exclusive; DCs and MΦ interact during inflammatory responses and 
the recruitment of cells, including additional DCs, MΦ, T-lymphocytes and NK cells.
The slower endocytic processes noted with DCs would certainly be favourable for efficient anti-
gen processing leading to presentation, as well as cytosolic translocation for cross-presentation 
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or facilitating RNA translation (see Figure 3). Yet, despite the difference in the cellular compo-
nents and the rate of endocytic processing, both clathrin-dependent and clathrin-independent 
pathways show a major relationship. Although some employ dynamin while other pathways 
are dynamin-independent [21–23, 78–80], both processing pathways can lead to interaction 
with early endosomes (Figure 3). This provides acidification by vacuolar H+-ATPase activity 
and enzyme-mediated degradation within the endocytic vesicle. The important difference 
between the rapid clathrin-dependent endocytosis and slower clathrin-independent routes is 
the rate at which endosomal interaction and acidification occur [21–23, 55–57]. The clathrin-
independent endocytic processes, such as macropinocytosis, lipid raft-dependent and caveo-
lae-mediated endocytosis, are notably active with DCs, facilitating processing of antigen for 
presentation via MHC Class II [9, 23, 54, 56, 57]. Moreover, slower processes support reten-
tion of endocytosed material at the earlier stages of endosomal maturation in DCs for longer 
periods, increasing the potential for cytosolic translocation. Nonetheless, clathrin-dependent 
endocytic processes have been employed by viruses to promote initiation of their infectious 
cycle. Ebola virus, coronaviruses and certain mammalian reoviruses employ clathrin-dependent 
endocytosis for their infections [81]. Other viruses, such as influenza virus, employ both 
clathrin-dependent [82] and clathrin-independent pathways, the latter proving also caveo-
lin-independent. Certain bacterial toxins are also endocytosed by clathrin-dependent and 
clathrin-independent pathways [26–28, 83–85].
6.1. Macropinocytosis in dendritic cells
The clathrin-independent macropinocytosis relates to clathrin-dependent endocytosis in 
 concentrating receptors upon internalisation, although macropinosomes are more heteroge-
neous in size—up to 5 μm diameter. The function of macropinocytosis also impacts strongly 
on DCs in their role of antigen processing for presentation to the adaptive immune system. 
Both DCs and MΦ employ macropinocytosis more efficiently than other cells [86], through 
their application of aquaporin channels to sample the environment [87], exhibiting fluid 
phase uptake up to 40% of their cell volume [88]. Macropinocytic activity is also important 
with respect to the aforementioned maturation of DCs which is essential for efficient antigen 
presentation to T-lymphocytes. Aquaporins are down-regulated in mature DCs, relating to 
the observed reduction in macropinocytosis [87]. In contrast, maturation of DCs does not 
affect other receptor-mediated endocytosis processes.
The fate of macropinosomes is also particular to DCs and MΦ, wherein macropinosomes 
fuse with early endosomes soon after formation (Figure 3). Macropinosomes acquire Rab7, 
exchanging their membrane content with late endosomes as they are transported to a more 
perinuclear area [89]. This contrasts with non-immune cells, such as epithelial and fibroblas-
tic cells, wherein macropinosomes tend to remain more isolated from endosomes and lyso-
somes, fusing back with the plasma membrane to release their content into the extracellular 
space [90, 91].
Clearly, macropinocytosis is an important component for facilitating antigen capture by 
DCs and MΦ. In the context of antigen processing and presentation, the macropinocy-
tosed antigens are observed in endocytic vesicles and macropinosome-like structures rich 
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in MHC Class II  molecules (Figure 3, pathway (b)) [88, 92]. Antigens endocytosed via 
 macropinocytosis can also be presented on MHC Class I molecules—the cross-presentation 
pathway following  antigen translocation to the cytosol for processing via the immuno-
proteosome (Figure 3, pathway (c)) [93]. Yet, DCs employ other endocytic pathways in 
addition to macropinocytosis (Figure 3). Caveolin-dependent endocytosis is important, 
as is lipid raft-mediated endocytosis, although the latter can be associated with both mac-
ropinocytosis and caveolar endocytosis. Clathrin-independent endocytosis routes in the 
absence of caveolin may become solely dependent on lipid rafts for intracellular trafficking.
6.2. Processing macropinosomes and other endocytic processes
Following the endocytosis, early endosomes associating with endocytic vesicles are considered 
key players for cargo sorting (see Figure 3). An important bifurcation of endocytic pathways 
occurs at this stage, channelling into Rab11+ recycling endosomes or into intra-luminal vesi-
cles of multi-vesicular endosomes (MVEs; or MVBs for multi-vesicular bodies). Via these lat-
ter structures, processing will ultimately lead into late endosomes and lysosomes. Many late 
endosomes are involved in the degradative pathway resulting in association of lysosomes and 
degradation of the cargo, but a late endosome-related structure is essential for MHC Class II 
presentation—the MHC Class II compartment (MIIC). Late endosomes may also be associated 
with transfer into vesicular structures carrying the internal TLRs. Moreover, the channelling 
of endocytosed antigen in a relatively intact form for delivery to B-lymphocytes employs late 
endosome-like structures [44, 45]. Not only macropinocytosis, but also caveolin-dependent 
endocytosis crosstalk with classical endosomal components [94], including fusion with Rab11+ 
recycling endosomes—caveolin+ caveosomes are also seen to be sorted from endosomal com-
partments [95].
Caveolar endocytosis has been noted with particular entities interacting with cells, includ-
ing albumin [96], tetanus toxin [97], cholera toxin [98] and both polyomavirus and SV40 
[99]. The uptake of cholera toxin [100] is particularly noteworthy, considering the involve-
ment of the recycling endosomes with caveolar endocytosis. The B subunit of the toxin 
is responsible for cell entry following binding to the monosialotetrahexosylganglioside 
(GM1) found in lipid rafts and caveolae. Although the CTB subunit can associate with 
clathrin-dependent endocytic vesicles and clathrin-coated pits [101], and inhibition of 
 clathrin-mediated endocytosis reduces cholera toxin internalisation [98, 102], the toxin 
activity it is not dependent on clathrin-dependent endocytosis [102]. For this, the cholera 
toxin must be delivered into Golgi complex, which requires retrograde transport from the 
recycling endosomes (Figure 3) [26–28]. In fact cholera toxin can be endocytosed by differ-
ent routes, but is ultimately delivered from recycling endosomes to Golgi complex via a 
clathrin-independent pathway [100, 103], as is shiga toxin [104]. It is also likely that viruses 
such as polyomavirus and SV40 may require similar routes of entry [105]. Overall, the 
important lesson from these studies is the capacity of DCs to employ different endocytic 
routes, some particular to certain antigenic materials, and others being employed in com-
bination. Whether the DCs employ a particular endocytic pathway or a number of different 
routes, the outcome is dependent on the pathway employed and therefore influences how 
the DCs handle the endocytosed cargo.
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7. Cytosolic translocation in dendritic cells
As mentioned above, retrograde transport from recycling endosomes into the Golgi and 
ER (see Figure 3) is an important pathway for the B subunit of cholera and shiga toxins to 
 promote cytosolic translocation of the A subunit [26–28]. Polyomavirus and SV40 also translo-
cate from the ER for initiation of their replicative cycle [105]. These pathways can be employed 
by DCs for the cytosolic translocation leading to cross-presentation of exogenous antigen.
Following the retrograde pathway, cytosolic translocation is likely dependent on protein-
protein interactions facilitating entry into the cytosol, as observed with the mechanisms 
employed by cholera and shiga toxins and members of the polyomaviridae. Association of 
ER membranes with endocytic vesicles can insert the ER dislocon, leading to antigen associated 
with ER-like structures and subsequent entry into cross-presentation pathways [39, 43].
Yet, DCs can also employ non-retrograde pathways–relatively slow clathrin-dependent endo-
cytosis or the clathrin-independent macropinocytosis–for cytosolic translocation leading into 
the cross-presentation pathways. This cytosolic translocation displays distinctive characteristics 
dependent on which of the endocytic routes is employed, but requires interaction with early 
endosomes. The neutral pH environment of the ER and proteolytic activity therein is clearly 
distinctive from the events associated with clathrin-dependent and clathrin-independent endo-
cytosis involving endosomal interactions. With the latter, the early endosomes provide mem-
brane vacuolar H+-ATPases promoting acidification of the endocytic vesicles, an essential event 
for facilitating cytosolic translocation from these arms of the endocytic processing pathways.
An important influence on the outcome of endocytic vesicles interacting with early endosomes 
is the role of cationic elements within virus particles or vaccine delivery vehicles. Cationic 
entities, associated with peptide, lipid or saccharide structures can provide what has been 
referred to as the ‘proton sponge’ or ‘pH-buffering’ effect (Figure 3, pathway (d)) [106, 107]. 
The vacuolar H+-ATPase activity from early endosomes pumps protons into the  endocytic 
vesicle leading to this proton sponge effect. For example, protonable amines behave as buff-
ering agents by readily accepting protonation [108]. Histidine- and  arginine-rich molecules, 
as well as histidine residues, can also initiate the proton sponge effect through protonation 
of imidazole rings [106, 107]. By increasing ion and water uptake into the endocytic vesicles, 
the protonation events increase osmotic pressure leading to vesicular swelling and membrane 
destabilisation, allowing cytosolic release of the vesicle contents. However, disruption of the 
endocytic vesicles would prove a relatively destructive process, and are not ideal for the intra-
cellular environment. A more physiologically appropriate  process can be seen when analysing 
histidine- and arginine-rich peptides and polymers, with which cytosolic translocation can be 
promoted through interaction with the anionic vesicular membrane [107]. This is particularly 
notable with amphiphilic peptides. Binding at the edge of membrane pores can reduce inter-
nal membrane tension, while insertion into the vesicular membrane can reduce chain length 
to create internal membrane tension [106, 109]. Cationic lipids will also influence cytosolic 
translocation by ionic paring with phosphatidylserine in endocytic vesicle membrane [110]. 
This promotes electrostatic interactions and decreases membrane curvature, potentially with 
conversion from a lamellar to a non-lamellar phase.
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Regardless of which endocytosis pathway is employed by the DC to process internalised 
cargo, the outcome will be either destruction or processing. For the latter, this can lead 
through the maturing endosomal system for MHC Class II presentation, or can involve one 
of the pathways of cytosolic translocation for MHC Class I presentation. With RNA viruses 
and RNA vaccines, the latter pathways would be more favourable, promoting delivery of the 
RNA to the ribosomal translation machinery. In the case of RNA vaccines, this translation 
would provide the antigens for direction into the immunoproteosome from the ER, or prob-
ably via autophagy into the endosomal system for delivery to the MIIC.
8. Dendritic cell endocytosis leading to MHC Class I or MHC Class II 
presentation
As mentioned above, MΦ with DCs employ common endocytic processes for ultimately 
distinctive outcomes [38]. While MΦ rapidly recruit and activate lysosomal proteases, 
leading to rapid degradation of endocytic cargo, the lower acidic endosomal pH and slower 
acidifying process within DCs favour slower degradation of internalized cargoes. DCs 
also generate reactive oxygen species in endocytic compartments through the activated 
NOX2 subunit of NADPH-oxidase, which in turn consume protons and modulate the pH. 
This rate of endosomal acidification is important for the consequences of the processing 
pathway, and therefore both directing into the MIIC and cytosolic translocation. Although 
acidification of the endosomal structures is a characteristic of the so-called endosomal 
maturation leading into the more destructive late endosomes and lysosomes, the early 
stages of the endosomal acidification play particularly essential roles for cytosolic translo-
cation from the endosomal compartment. Therefore, a more ‘regulated’ (in terms of rate) 
endosomal acidification would facilitate the processing events leading to MHC Class I 
and MHC Class II presentation. Importantly however, once the acidification falls below a 
certain pH, the potential for translocation to the cytosol becomes less likely, and the endo-
somal structures become ‘cross-presentation incompetent’ [38]. This situation relates to the 
concomitant decrease of pH and ER-derived proteins, with increased proteolytic activity.
It is now clear that exogenous antigen can be processed into the MHC Class I pathway 
via ‘cross-presentation’ pathways [40, 43, 57, 58, 111] which is important for activating 
the Tc lymphocytes of cytotoxic CMI (see Figure 1). Consideration of these characteristics 
has also proven valuable for understanding the requirement of endocytosed RNA and 
RNA viruses for cytosolic translocation (see Figure 3, pathway (d)). Moreover, the division 
of labour associated with different DC subsets is an important consideration when cytosolic 
translocation is required. Participation of different DC receptors leading to endocytosis is 
influential, defining the form of endocytosis and relative role played by retrograde transport 
into the ER [43].
When the receptor and endocytic targeting deliver into early compartments such as recy-
cling endosomes, both MHC Class I and Class II presentation can ensue; delivery into and 
interaction with later endosomal compartments lead to a domination of MHC Class II pre-
sentation [38, 112]. Yet, transport of the endocytosed material down a particular pathway 
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favouring MHC Class I or MHC Class II processing is not absolute. For example, material 
being  transported towards an MHC Class I presentation pathway can be transferred into 
autophagic vesicles for delivery into the MHC Class II presentation pathway.
Overall, it can be considered that processing antigen for association with MHC Class I molecules 
is a less acidic process compared with the pathway leading to MHC Class II presentation. 
A good example of this is the aforementioned relative neutral pH of the retrograde pathway 
though the ER. Another example is seen with cytosolic translocation from early endosomal 
structures. The initial lowering of endocytic vesicle pH is important, but as mentioned above 
this is limited by the ‘point of no return’ within the acidifying endosomal compartment, 
beyond which the conditions render translocation less likely [38, 43, 113]. Therefore, cytosolic 
translocation must arise before the more degradative processes of the late endosomes have 
taken charge.
As mentioned above, not only antigen, but also viruses employ different endocytic pathways 
to initiate their replicative cycles. While polyomaviruses and SV40 translocate from the ER 
for this purpose, numerous other viruses require the acidifying endosomal system to initi-
ate their replication. The endosomes provide pH-dependent modifications of viral surface 
proteins. By such means, endosomal membrane modulation is promoted leading to cytosolic 
release of the viral genome; in the case of positive strand RNA viruses, the genome func-
tions as a mRNA by interacting directly with the cellular translation machinery; in the case 
of negative strand viruses, the viral genome is associated with the nucleocapsid carrying 
the polymerase, the polymerase generating the ‘positive strand’ to function as an mRNA. 
Endosomal membrane modulation can result from fusion between the endosomal and viral 
membranes, as with influenza virus, or re-arrangement of viral proteins to form ion channels 
and pores in the endosomal membrane, as with picornaviruses and flaviviruses [25]. Related 
to the former (endosomal membrane fusion), is the work with fusogenic peptides, leading to 
vesicular membrane destabilisation as the internal pH decreases below 6.0 [107, 109].
These studies on the processes employed by viruses to promote cytosolic translocation have 
proven useful in the development of processes for the successful delivery of RNA vaccines. 
In this context, the delivery of self-amplifying replicon RNA is of particular interest, due 
to its high potential for vaccine development in the future [9, 13, 17–19, 35, 114]. However, 
these large RNA molecules have particular requirements, which are more stringent or more 
 obligatory than with smaller RNA molecules such as the oligonucleotides of siRNA and 
mRNA vaccines.
9. Self-amplifying RNA interaction with dendritic cells
Interest in the development of replicating RNA vaccines has increased during the past two 
decades, notably in the field of self-amplifying RepRNA technology [9, 13, 18, 114–118]. 
RepRNA are basically viral genomes lacking at least one gene encoding structural proteins, 
but retaining the genes encoding the viral polymerase (self-amplification/replication) complex 
(Figure 6), hence termed as ‘replicon’. This type of construct permits replication of RNA 
 without the risk of progeny virus production and therefore disease; the vaccine element is 
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introduced by inserting genes encoding vaccine antigens of interest (‘genes of interest’ or 
GOI) into the constructs (Figure 6) [9, 13, 18, 20, 114–121]. Development of this technology 
during the past two decades focussed on packaging the RNA in a virus-like particle or the 
virus replicon particle (VRP) [9, 115–117]. However, this approach can encounter particu-
lar problems such as host immunity against the viral proteins composing the VRP surface 
structure; production difficulties/expense may also prove an encumbrance due to the require-
ment for complementing cell lines providing the gene products missing from the replicon so 
that VRPs will be generated [9]. Replacement of the VRP by biodegradable delivery vehicles 
would facilitate vaccine production (obviating the need for complementing cells lines), avoid 
problems of the host immune system neutralising the VRP antigens, and permit more con-
trollable targeting of DCs [9]. This approach was first reported in 2008 (Figure 7) [20], with 
Figure 6. Generation of self-amplifying RepRNA vaccines derived from the CSFV genome, for application with 
biodegradable nanoparticulate delivery vehicles to target DCs by nanoparticulate vehicles. Two examples are shown: 
∆Erns replicon lacking a single (Erns) gene, and C-Igκss-p7 replicon lacking all three structural glycoproteins. NotI 
endonuclease restriction sites, introduced to facilitate insertion of genes encoding vaccine antigen, are shown at the 
3’ end of the Npro leader autoprotease as N*. The site for insertion of the gene of interest (GOI) encoding the vaccine 
antigen is shown as the hashed box. An additional insertion, an EMCV IRES, is employed to restart the translation which 
terminates after the GOI.
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Figure 7. Nanoparticulate delivery of self-amplifying RNA vaccines derived from the CSFV RepRNA. The nanoparticulate 
delivery vehicle is designed to promote efficient uptake into endocytic vesicles, in which the RepRNA is seen to 
accumulate. Thereafter, a gradual cytosolic translocation of the RepRNA is observed—essential for RNA delivery to the 
intracellular site for translation. Thereby, the RepRNA efficiently translates the encoded vaccine antigen of interest, as 
well as the polymerase complex for replication of the RNA. Insertion of an internal ribosomal entry site (IRES) from EMC 
virus ensures that translation of the polymerase complex resumes after translation of the vaccine antigen.
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increasing evidence of the potential for this methodology forthcoming in more recent years 
[9, 13, 17–19, 33–35, 114, 122].
RepRNA show the characteristics of the parent virus genome, providing several rounds of 
replication to increase the number of RNA templates available for translation. By such means, 
the antigen dosages available for activating humoral immunity and cytotoxic cell-mediated 
immunity (CMI), as well as the duration of that availability, are enhanced beyond that pos-
sible with a more conventional inactivated vaccine approach (Figure 8) [9, 13, 17, 18, 20, 114]. 
Moreover, being replicative in nature enhances their capacity to induce CMI as well as humoral 
immunity, a characteristic often lacking with inactivated vaccines. Live, attenuated vaccines 
offer the same advantage due to their replicative nature. A major benefit of RepRNA vaccines 
is that they do not suffer from the potential risk of reversion to virulence posed by attenuated 
vaccines, due to their defective nature being unable to produce progeny viruses (Figure 6).
Many studies, primarily using VRPs, have employed alphaviruses [115–117]. However, these 
viruses and the derived RepRNA are cytopathogenic, killing their host cells. The slow pro-
cessing and retention of antigen typical of DC functionality with respect to inducing robust 
immune defences would not be favoured by cell death from a cytopathogenic RepRNA, 
despite their rapid production of antigen. Although delivery of such replicons to epithelial 
cells would provide antigen indirectly for the DCs, targeting DCs with cytopathogenic repli-
cons is probably not the most effective of approaches. On the other hand, non-cytopathogenic 
RepRNA vaccines, such as those derived from classical swine fever virus (CSFV) (Figure 6) 
[20, 118], would have higher potential for targeting DCs with the aim of prolonged presence 
of antigen in these cells (Figure 7). While non-cytopathogenic RepRNA should translate anti-
gen slower than cytopathogenic replicons, lower antigen production levels fit well to the DC 
requirements for prolonged antigen presentation to the adaptive immune system (Figure 8).
One major drawback with RepRNA vaccines in general is their high RNase sensitivity. This 
can be avoided by employing either VRP for delivery or biodegradable nanoparticulate deliv-
ery vehicles (Figure 7) [9, 13, 18, 20, 114, 123]. From initial efforts in 2003, the concept of 
RepRNA delivery by biodegradable nanoparticles was developed [20], showing high poten-
tial for delivery to DCs (Figure 7; Figure 8) [9, 13, 18, 114, 17]. Nonetheless, it is now evident 
that nanoparticulate technology can lead to compaction of RepRNA (Figure 7). This was not 
so apparent with delivery of smaller RNA molecules, such as siRNA and mRNA, only coming 
to light with the much larger RepRNA molecules. While compaction with the delivery vehicle 
could interfere with cytosolic translocation, even after the translocation a lack of decompaction 
would interfere with ribosomal entry and thus translation. Studies turned to the aforemen-
tioned importance of protonation within the endocytic vesicle for cytosolic translocation, 
which could also influence the degree of RNA compaction by the delivery vehicle.
Application of cationic components in the delivery vehicles for RepRNA, such as chitosan 
cores, cationic lipids and cationic polyplexes (Figure 7), has proven successful for enhancing 
RepRNA delivery [9, 17–19, 33, 35]. Their cationic nature facilitates interaction with RNA 
and protection from RNases. In addition, they may favour events leading to cytosolic trans-
location from the endocytic vesicles during the initial phases of early endosome-mediated 
acidification. Application of additional cationic entities, such as lipids or peptides, may further 
favour cytosolic delivery and decompaction for translation, potentially by reducing the levels 
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of compaction obtained by a single cationic entity. Certainly, the presence of cationic lipids 
in a chitosan-based nanoparticulate delivery vehicle with RepRNA enhanced both the in vitro 
translation of the delivered RNA, and the induction of humoral and CMI immune defences in 
vivo (Figure 7; Figure 8) [18].
10. Conclusion: dendritic cell endocytosis promoting cross-presentation 
and RNA translation
Dendritic cells, in particular the cDC1 subset, display the capacity for cross-presentation 
of exogenous antigenic material (Figure 1). Using SVLPs, DCs primarily endocytose these 
vaccines via macropinocytosis, but an underlying additional endocytic process is also active 
[14]. While a dominant processing towards MHC Class II presentation is evident, cross-
presentation pathways also exist, directing the processing towards MHC Class I presenta-
tion [15]. Importantly, these SVLPs do not activate the DC family to promote DC maturation 
which is essential for efficient induction of adaptive immunity. By modifying the lipopeptide 
Figure 8. Overview of the procedures for association of RepRNA vaccines with biodegradable nanoparticulate delivery 
vehicles, targeting DCs to promote induction of both humoral and cytotoxic immune defences.
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monomers of the SVLPs to carry TLR2 ligands, certain SVLPs are directed into internal TLR2-
containing sites for induction of cytokines that are important for DC maturation [15].
The endocytic processes involved in the cytosolic translocation of endocytosed antigen also 
relate to the delivery of RNA required for translation. RNA vaccines and the genomes of RNA 
viruses must translocate from the endosomal system or ER (retrograde transport) following 
endocytosis, to facilitate delivery into cytosolic sites of ribosomal translation (Figure 3). With 
viruses, this can be promoted by the interaction of viral surface proteins with the endosomal 
membrane, becoming modified upon acidification by early endosome to create ion channels 
and/or pores in the membrane for cytosolic transfer of the RNA genomes. RNA vaccines can 
employ similar strategies, when the RNA is packaged within virus-like particles, which can 
be seen with self-amplifying replicon RNA vaccine delivery as VRPs. With synthetic RNA 
vaccines, delivered by synthetic nanoparticulate delivery vehicles rather than VRPs or other 
virus-like particles (Figure 7), translocation must occur as the interaction of the RNA with its 
delivery vehicle becomes weakened to the point of promoting decompaction. There is a criti-
cal point of no return, with cytosolic translocation being vital before late endosomal activity 
dominates. Therefore, the delivery vehicle formulation must facilitate endosomal membrane 
modification to permit this cytosolic translocation at the appropriate stage of endosomal 
maturation.
An important issue pertinent to nanoparticle delivery is the size of the delivery vehicle being 
endocytosed. Size and ionic potential of particles interacting with cells, particularly DCs and 
MΦ, influence both the endocytic route and how the cell handles internalised material [43, 
58]. The smaller the entity the greater the role played by retrograde transport from endocytic 
vesicles into the ER [58]. Macropinocytosis and caveolar endocytic delivery to the ER may 
occur without interaction with early endosomes, or shortly after acidification begins (Figure 3). 
Nonetheless, if the delivery vehicle is designed to promote cytosolic translocation and even 
decompaction when present in an acidifying environment, then RNA delivery should be 
directed into macropinosomes and caveolar vesicles interacting with early endosomes.
Overall, self-amplifying RepRNA delivery to DCs has high potential for future vaccine 
development and application, providing controlled and efficacious vaccine delivery, and 
thus promoting robust immune defence induction (Figure 8). Of particular importance is 
the appropriate application of nanoparticulate delivery vehicle formulations to enhance 
cytosolic translocation of RNA vaccines in DC, while reducing compaction to ensure 
 ribosomal entry for translation of the encoded vaccine antigens and self-amplification of 
the replicon RNA.
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